Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Plerixafor 8HCl (formerly JM-3100; AMD-3100; SDZ-SID-791; JLK-169; SID-791; JM-2987; MOZOBIL), the hydrochloride salt of Plerixafor, is a specific chemokine receptor CXCR4 antagonist used as an immunostimulant to mobilize hematopoietic stem cells in cancer patients into the bloodstream. In cell-free assays, it inhibits CXCR4 and CXCL12-mediated chemotaxis with IC50s of 44 nM and 5.7 nM, respectively.
Targets |
125I-CXCL12-CXCR4 ( IC50 = 44 nM ); 125I-CXCL12-CXCR4; HIV-1 (NL4.3 strain) ( IC50 = 9 nM ); HIV-1 ( EC50 = 1-10 nM ); HIV-2 ( EC50 = 1-10 nM )
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Cell Assay |
U87MG cells are treated with CXCL12, Plerixafor, or peptide R, as mentioned in the previous "Treatments" section, after being seeded in 96-well plates at a density of 6x103 cells in 200 μL/well. During the last two hours of treatment, MTT (5 μg/mL) is added at 24, 48, and 72 hours. Following the removal of the cell medium, 100 μL of DMSO is added, and an LT-4000MS Microplate Reader is used to measure the optical densities at 595 nm. Triplicate measurements are taken from three separate experiments[2].
|
|
Animal Protocol |
|
|
References |
|
Molecular Formula |
C28H54N8.8HCL
|
|
---|---|---|
Molecular Weight |
794.47
|
|
Exact Mass |
794.25
|
|
Elemental Analysis |
C, 42.33; H, 7.87; Cl, 35.70; N, 14.10
|
|
CAS # |
155148-31-5
|
|
Related CAS # |
Plerixafor; 110078-46-1
|
|
Appearance |
White solid powder
|
|
SMILES |
C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CN3CCCNCCNCCCNCC3.Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl
|
|
InChi Key |
UEUPDYPUTTUXLJ-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C28H54N8.8ClH/c1-9-29-15-17-31-13-3-21-35(23-19-33-11-1)25-27-5-7-28(8-6-27)26-36-22-4-14-32-18-16-30-10-2-12-34-20-24-36;;;;;;;;/h5-8,29-34H,1-4,9-26H2;8*1H
|
|
Chemical Name |
1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;octahydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 120 mg/mL (151.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
Solubility in Formulation 2: Saline: 30 mg/mL  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.2587 mL | 6.2935 mL | 12.5870 mL | |
5 mM | 0.2517 mL | 1.2587 mL | 2.5174 mL | |
10 mM | 0.1259 mL | 0.6294 mL | 1.2587 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06141304 | Active Recruiting |
Drug: Plerixafor | Relapsed Adult ALL Relapsed Adult AML |
The First Hospital of Jilin University |
September 1, 2023 | Phase 2 |
NCT02193191 | Active Recruiting |
Drug: Plerixafor | Sickle Cell Disease | Memorial Sloan Kettering Cancer Center |
September 2014 | Phase 1 |
NCT03182426 | Active Recruiting |
Drug: Plerixafor Drug: Alemtuzumab |
Diabetes Mellitus, Type 1 | University of Alberta | August 15, 2017 | Phase 1 Phase 2 |
NCT03653247 | Active Recruiting |
Drug: Busulfan Biological: Plerixafor |
Sickle Cell Disease | Sangamo Therapeutics | March 6, 2019 | Phase 1 Phase 2 |
NCT02570542 | Active Recruiting |
Drug: Plerixafor Drug: G-CSF |
Myeloma | University of Chicago | July 12, 2011 | Phase 1 |